Interventions for congenital heart disease started in 1966 when Raskind and Miller performed balloon atrioseptostomy in patients with transposition of great arteries. Kings and Mills were the first to describe transcatheter closure of atrial septal defect in 1976. In 1982, Kan et. Al. performed the first balloon dilation in patients with valvular pulmonary stenosis. In Taiwan, balloon dilation has become a routine treatment for congenital heart disease since 1985. Congenital stenosis of the valves and great arteries have been effectively treated with balloon dilation technique. Stents have been applied in the treatment of postoperative branch pulmonary artery stenosis and coarctation of the aorta. The results of stenting were comparable to those of surgery. However, shortage of stent supply in Taiwan is a major problem and it remains to be solved by our Government. With the development of devices and advancement of techniques, transcatheter closure of abnormal shunts has gained wide acceptance as first line therapy in atrial septal defect (ASD), ventricular septal defect (VSD), patent ductus arteriosus (PDA) and coronary arteriovenous fistula. Simple shunt lesions have now treated with transcatheter techniques with excellent results and surgery is reserved for those with low body weight and large shunt or failure cases of transcatheter treatment. Hybrid treatment has been performed with good results for infants with large muscular VSD. Recently, transcatheter replacement of pulmonary valve has become as an alternative to surgical valve replacement for pulmonary valve dysfunction. However, there were very few valves approved by FDA. Moreover, the diameters of the currently available valves (Melody valve or Sapient valve) were too small to be implanted in our patients because a transcatheter patch was used in surgical repair to relieve infundibular and valve stenosis in patient with tetralogy of Fallot. Therefore, several self-expandable valves are undergoing development, such as Venus P-Valve and Pulsta valve, for patients with a larger pulmonary annulus. In the very near future, new valves will be available for pulmonary valve replacement in several pulmonary regurgitation patients with a large annulus.